Theravance Biopharma, Inc. (TBPH)
19.66
+0.23
(+1.18%)
USD |
NASDAQ |
Feb 20, 16:00
19.69
+0.03
(+0.15%)
After-Hours: 20:00
Theravance Biopharma SG&A Expense (Quarterly) : 18.33M for Sept. 30, 2025
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Corcept Therapeutics, Inc. | 123.98M |
| Nektar Therapeutics | 16.07M |
| Innoviva, Inc. | 27.29M |
| Oramed Pharmaceuticals, Inc. | 1.274M |
| Moderna, Inc. | 308.00M |